fda warning letters glp-1 september 2025 FDA takes aim at telehealth companies for promoting unofficial weight loss drug dupes

FDA issued 30 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. This marks the second round of enforcement action since the agency's September crackdown on misleading

21.25

★★★★☆4.8 (126)

Prescription Drug Freight Fraud Report, September 2025 – Partnership for Safe Medicines

28.81

★★★★★4.9 (98)

FDA Warning Letter Breakdown: Sterility Failures, Subpotent GLP-1 Drugs, and a Compounding Pharmacy Operating Without Control

27.65

★★★★★5.0 (157)

Thinking about buying GLP-1 and other products labeled “for research purposes” or “not for human consumption”? Think again. These products have not been reviewed by FDA for safety, effectiveness or

26.65

★★★★★4.7 (84)

Thinking about buying GLP-1 and other products labeled “for research purposes” or “not for human consumption”? Think again. These products have not been reviewed by FDA for safety, effectiveness or quality and

24.23

★★★★★4.9 (203)

September 15, 2025: Telehealth company must stop implying its compounded GLP -1 is FDA-approved, warns FDA – Partnership for Safe Medicines

23.17

★★★★★5.0 (176)

FDA Drug Recalls and Warnings: Illegal GLP-1 Sales and Misleading Marketing by Novo Nordisk and Eli Lilly

21.03

★★★★★4.8 (132)